Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy

This study is looking at how cisplatin, a chemotherapy drug, affects your nerves. It uses a special test called Threshold Tracking Nerve Conduction Studies (TTNCS) to measure nerve excitability. This helps researchers understand why some people develop cisplatin-induced peripheral neuropathy (cis-PN), a condition causing burning or tingling in hands and feet. The study wants to find early signs of nerve damage. You can join if you are an adult starting cisplatin chemotherapy or if you have already had cisplatin and are experiencing cis-PN. The main goal is to see if there's a change in your nerve excitability compared to before treatment or at the time of the test. The study plans to enroll 60 participants.

Study design: This interventional study plans to enroll 60 participants. It is not specified if it is randomized or blinded.
What's involved: You would have screening, in-clinic visits, blood tests, questionnaires, standard neurological exams, and Threshold Tracking Nerve Conduction Studies. For some, these are done at baseline and within 24 weeks of starting cisplatin.
Compensation: Not stated in the trial record.
Follow-up: For participants starting cisplatin, nerve excitability is measured at baseline and within 24 weeks of starting treatment. For others, it's during the TTNCS procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy

Recruiting

NAAges 18+InterventionalDiagnostic

Ka-Wai Ho

~60 participants

Updated 2026-04-22 on ClinicalTrials.gov

What's tested:Threshold Tracking Nerve Conduction Studies

At a glance

Recruiting sites

1 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Presence of change in Nerve Excitability in comparison to baseline nerve excitability.

Measured over For Arm A, the time frame is at baseline and within 24 weeks of cisplatin initiation. For Arm B, the time frame is during the TTNCS procedure.

Conditions

Peripheral Neuropathy Due to Chemotherapy

Peripheral Neuropathy

Neurotoxicity Syndromes

Neuropathy

Where it's being run

2 sites across 1 states

Massachusetts2

Study leadership

Ka-Wai Ho, MD · PRINCIPAL_INVESTIGATOR · Beth Israel Deaconess Medical Center
Tamar Berger, MD PhD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Ka-Wai Ho, MD

[email protected]

617-667-1665

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Adults age ≥ 18 who will begin cisplatin-based chemotherapy either alone or in combination with other agents that are not known to cause neuropathy.

Participants must have adequate hematologic parameters to allow chemotherapy.

Adults age ≥ 18 with a diagnosis of cis-PN.

The last dose of cisplatin must be ≥ 3 months prior to study enrollment. Patients who may have been previously enrolled in Cohort A of this study are eligible to participate in Cohort B if they continue to have cis-PN symptoms 3 months after completion of cisplatin therapy.

Exclusion

Pre-existing peripheral neuropathy;

Family history of a genetic/familial neuropathy;

Any contraindication for treatment with cisplatin as determined by their primary oncologist;

Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;

Patients with cardiac or spinal stimulating devices;

Women who are pregnant or breastfeeding;

Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;

Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;

Patients not considered to be able to comply with the protocol.

Pre-existing peripheral neuropathy;

Family history of a genetic/familiar neuropathy;

History of cisplatin-based regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;

Patients with cardiac or spinal stimulating devices;

Women who are pregnant or breastfeeding;

Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;

Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;

Patients not considered to be able to comply with the protocol.

What this trial measures

Presence of change in Nerve Excitability in comparison to baseline nerve excitability.For Arm A, the time frame is at baseline and within 24 weeks of cisplatin initiation. For Arm B, the time frame is during the TTNCS procedure.
Nerve excitability will be assessed via Threshold Tracking Nerve Conduction Study (TTNCS). Excitability parameters collected will include refractoriness, superexcitability, extent of threshold change in threshold electrotonus (hyperpolarizing 90-100ms). A composite excitability score is calculated to assess overall change in excitability parameters, all of which are weighted equally (Park, S.B., Lin, C.S.Y., Kiernan, M.C. Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity.J. Vis. Exp. (62), e3439, doi:10.3791/3439 (2012).

Trialytics